Patients with progressive multiple sclerosis experience relentless disability worsening.
Although current FDA-approved therapies for MS prevent relapses, very few help slow down disability worsening in patients with progressive forms.
Biological processes leading to insidious worsening of disability in progressive MS are largely unknown, limiting the development of drugs.
One strategy to slow down disability worsening is to find neuroprotective agents, i.e., drugs that render nerve cells more resistant to injury.
Educational Session on Progressive MS: Click here to watch
NAC in Progressive MS Trial (NACPMS)
We designed a proof-of-concept trial in progressive MS of high-dose N-acetyl cysteine (NAC) as an add-on to standard of care .
The study was conducted at UCSF and UC San Diego and sponsored by the Department of Defense and NMSS. Trial registration: NCT05122559.
Enrollment for this trial is now complete. We expect to share preliminary results in the summer of 2027.
Goals of the NAC in progressive MS (NACPMS) trial:
- Identify preliminary evidence that NAC prevents brain atrophy and gait worsening compared with placebo.
- Confirm that an antioxidant treatment strategy may benefit patients with progressive MS.
- Confirm whether a novel multi-sensor device is more sensitive than traditional measures to detect disease progression.
*******
Pseudorelapses in progressive MS:
Symptoms resembling new relapses may be pseudorelapses; stay tuned for updates on our upcoming study on the role of urinary tract infections in MS worsening.
Key Publications:
Schoeps VA, Graves JS, Stern WA, Zhang L, Nourbakhsh B, Mowry EM, Henry RG, Waubant E. N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial. Contemp Clin Trials. 2022 Nov;122:106941. doi: 10.1016/j.cct.2022.106941. Epub 2022 Sep 28. PMID: 36182028.